Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Graham Dellaire who wrote (698)	3/15/2000 9:03:00 AM
From: Chip McVickar	Respond to of 1154

Graham, I believe the sell off was over questions of valuation. Momentum players bought these stocks on future valuation and momentum, not for their medical "warm spot." There may well be a solid bounce as wise buyers return, but this sector as a road runner was just stopped cold. When parabolic charts end this way, history suggests the damage is long term. I do not expect to see GENE at 75 for a long time to come. This was also a sector event and damage will extend across the board. Furthermore, it may well effect the NASDAQ as well, and provide one the keys that alters the psychology of the players buying the momentum and valuation models being used to purchase tech and the new age stocks..! As I write there is no substantive buying of index futures as one would expect after a significant decline. This has been an unnecessary and pathetic attempt to manipulate the public for political gain and to obtain the philosophical high ground in a fading carrier of Bill Clinton. There was absolutely "NO"...."NO" reason for that speech to be presented at this time.....any substantive arguments could have been carried out quietly until an understanding was established. This was a typical 'philosophically high ground' stand by Clinton and may unwittingly unwind the markets that are so important to Clinton and his parties future prospects. Chip Related articles: cbs.marketwatch.com In another article: >>But there were some, like Telmeafbl, who saw the news as a real momentum killer: "Bottom line. NO support. This sector is dead for a long time. The thrill of genomics and that related to genomics research is over. ITS FREE. oh well."<< And Again: >>"Unfortunately or fortunately, in this country, healthcare has been nearly declared a right rather than a privilege. The companies involved in this sector therefore will always be governed by different standards as opposed to other non-health related fields. In other words, any new life saving technologies developed by biotech or drug companies will not be allowed to be withheld from the public for the sake of profit. If you believe this, you will come to the realization that biotech deserves a much lower valuation than software, or Internet-related industries, and that the correction occurring today was inevitable."<< Full Story: marketwatch.newsalert.com